1. Home
  2. FFWM vs LYEL Comparison

FFWM vs LYEL Comparison

Compare FFWM & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Foundation Inc.

FFWM

First Foundation Inc.

HOLD

Current Price

$5.90

Market Cap

473.3M

Sector

Finance

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$16.32

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FFWM
LYEL
Founded
1990
2018
Country
United States
United States
Employees
485
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
473.3M
556.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
FFWM
LYEL
Price
$5.90
$16.32
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$6.17
$30.60
AVG Volume (30 Days)
4.3M
52.0K
Earning Date
04-29-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$34,373,000.00
$36,000.00
Revenue This Year
$56.34
N/A
Revenue Next Year
$10.68
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.59
$0.40
52 Week High
$6.72
$45.00

Technical Indicators

Market Signals
Indicator
FFWM
LYEL
Relative Strength Index (RSI) 51.22 26.21
Support Level $5.44 $15.82
Resistance Level $5.97 $19.02
Average True Range (ATR) 0.19 1.27
MACD 0.03 -0.43
Stochastic Oscillator 80.63 12.55

Price Performance

Historical Comparison
FFWM
LYEL

About FFWM First Foundation Inc.

First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: